Notice of Intent to Sole Source - EzPlaz
Responses closed . Full description on SAM.gov.
Overview
- Response deadline
- 3:00 PM EDT
- Posted
- September 1, 2026
- Notice type
- Special Notice
- NAICS
- 325412: Pharmaceutical Preparation Manufacturing
- Agency
- Department of WarDEFENSE HEALTH AGENCY (DHA)
Notice details
- Office
- DEFENSE HEALTH AGENCY
- Place of performance
- Maryland, 21702
- PSC
- 6505: DRUGS AND BIOLOGICALS
- Last updated
- Oct 28, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- HT942726QE015
- Notice ID
- 5dda764058414494a13827d6b4ad2a6e
Description
The Defense Health Agency (DHA) Contracting Activity (DHACA), on behalf of the DHA’s Portfolio Acquisition Executive Medical Products (PAE MP), intends to issue a firm-fixed price Indefinite Delivery/Indefinite Quantity contract on a sole source basis under the authority of the Revolutionary Federal Acquisition Regulation (FAR) Overhaul, FAR 6.103-1, only one responsible source and no other supplies or services will satisfy agency requirements, to Vascular Solutions LLC, 6420 Sycamore Ct N, Maple Grove, Minnesota 55369-6032.
Vascular Solutions, LLC is the only source able to meet the Government’s requirements. The Government has a has a critical requirement for supply of a Food and Drug Administration (FDA) approved Freeze Dried Plasma (FDP) product for transfusion when plasma is required and other plasma products are not available. The FDA approved Vascular Solutions, LLC FDP product, EZPLAZ™, on 29 July 2026. Vascular Solutions LLC holds the first and only FDA-approved (licensed) FPD product on the market.
This Notice of Intent is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to perform the required work. Responses must be supported with clear and convincing evidence articulating the ability to provide FDA approved FDP product. Capability statements shall not exceed 5 (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source contract. If no written responses are received by the date listed below, an Indefinite Delivery/Indefinite Quantity contract will be awarded without further remark.
Capability statements are due by 3:00 PM local time, 16 September 2026. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to the following address: timothy.j.kelly169.civ@health.mil and shannon.p.lertora.civ@health.mil.
Award Overview
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Documents
No documents available.
Lifecycle
- 4Version 4Sources SoughtArchived
EzPlaz Freeze Dried Plasma FDA Approved
- 2Version 2Special NoticeCurrent
Type changed from Sources Sought to Special Notice
Notice of Intent to Sole Source - EzPlaz
Similar Opportunities
Additional Details
Solicitation Number
HT942726QE015
Archive Date
Jan 1, 2027
Office Address
FORT DETRICK, MD, 21702